[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609786":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":45,"responsibleParty":71,"collaborators":26,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":26,"enrollmentInfo":83,"targetDuration":26,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Washington University School of Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Auricular VNS Stimulation","EXPERIMENTAL","Participants receive twice-daily auricular vagal nerve stimulation",[13],"Device: Auricular Vagus Nerve Stimulation",{"label":15,"type":16,"description":17,"interventionNames":18},"Sham Auricular VNS Stimulation","SHAM_COMPARATOR","Participants will have an auricular vagal nerve stimulator placed in their ear twice daily, without the stimulation applied",[19],"Device: Sham Auricular Vagus nerve Stimulation",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Auricular Vagus Nerve Stimulation","Transcutaneous auricular vagal nerve stimulation",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Sham Auricular Vagus nerve Stimulation","Transcutaneous auricular vagal nerve ear clip applied without current\u002Fstimulation",[15],[32],{"name":33,"affiliation":5,"role":34},"Eric Leuthardt, MD MBA","STUDY_CHAIR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Raj Dhar, MD","CONTACT","314-362 2999","dharr@wustl.edu",{"name":42,"role":38,"phone":43,"phoneExt":26,"email":44},"Anna Huguenard, MD","314-362-3570","ahuguenard@wustl.edu",[46],{"facility":5,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","St Louis","Missouri","63110","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-90.19789,38.62727,{"lat":57,"lon":56},[60,64,67,69],{"name":61,"role":38,"phone":62,"phoneExt":26,"email":63},"Juliana Amaral Passipieri, PhD","314-747-1443","ajuliana@wustl.edu",{"name":65,"role":38,"phone":43,"phoneExt":26,"email":66},"Elma Heric, BS","elmah@wustl.edu",{"name":33,"role":68,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"name":37,"role":70,"phone":26,"phoneExt":26,"email":26},"SUB_INVESTIGATOR",{"type":72,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100609786","transcutaneous-auricular-vagus-enhanced-recovery-in-the-neuroicu-100609786",false,"NCT07219108","Transcutaneous Auricular Vagus Enhanced Recovery in the NeuroICU","The TAVERN Trial: Transcutaneous Auricular Vagus Enhanced Recovery in the NeuroICU - A Study of Clinical Outcomes and Cost Reduction","TAVERN","Inclusion Criteria:\n\n* Age ≥18\n* Admission to the NeuroICU within 36 hours of onset of an acute medical condition.\n* Patient or authorized legal representative should be able to provide consent within 36 hours of ICU arrival\n* Presence of at least one predictor of critical illness and\u002For severe brain \u002F spinal cord injury:\n\n  * Glasgow Coma Scale GCS \\>3 \\& \\\u003C= 12 at admission\n  * NIH stroke scale of 6 or greater\n  * Requirement for ongoing mechanical ventilation\n  * Requirement for ongoing vasopressor support\n  * Diagnosis of subarachnoid hemorrhage\n  * Diagnosis of intracerebral hemorrhage with hematoma volume \\> 5 ml\n  * Diagnosis of moderate-severe traumatic brain injury (GCS \\>3 \\& \\\u003C= 12)\n  * Refractory Status epilepticus requiring continuous sedative infusions\n\nExclusion Criteria:\n\n* Systemic immunosuppression\n* Receiving ongoing cancer therapy\n* Implanted electrical device (e.g., pacemaker, stimulator)\n* Bradycardia on admission (Sustained bradycardia on arrival with a heart rate \\\u003C 50 bpm for \\>5 minutes)\n* Risk of imminent death or limitation of care (e.g., Glasgow Coma Scale of 3, pupillary dilatation)\n* Expected ICU stay of less than 72 hours, as determined by attending physician or ICU fellow\n* Pregnancy\n* COVID-19","ALL","18 Years",{"count":84,"type":85},160,"ESTIMATED","INTERVENTIONAL",[88],"NA","This study will demonstrate the impact of taVNS on reducing adverse events in NeuroICU patients, determine if taVNS reduces length of stay, and quantify the economic benefits of taVNS implementation in a broader neurocritical care population.",[91,92],"Acute Neurological Injury","Acute Medical Conditions",[94,95,96,97,98,99,100,101,102],"vagal nerve stimulation","pathologic process","acute medical condition","brain diseases","central nervous system diseases","spine cord injury","vascular diseases","hemorrhage","acute neurological condition","2025-10-20",{"date":105,"type":106},"2025-10-21","ACTUAL",{"date":108,"type":106},"2025-09-24",{"date":110,"type":85},"2027-09-23",{"name":5,"class":6},1]